RVL Pharmaceuticals plc (RVLPQ)
- Previous Close
0.0000 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.9600 - Volume
600 - Avg. Volume
30,948 - Market Cap (intraday)
111 - Beta (5Y Monthly) 1.02
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 15, 2024 - May 19, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
www.rvlpharma.comRecent News: RVLPQ
Performance Overview: RVLPQ
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RVLPQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RVLPQ
Valuation Measures
Market Cap
55.70k
Enterprise Value
39.04M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.00
Price/Book (mrq)
0.00
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-184.91%
Return on Assets (ttm)
-23.65%
Return on Equity (ttm)
-182.44%
Revenue (ttm)
36.92M
Net Income Avi to Common (ttm)
-68.27M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
19.16M
Total Debt/Equity (mrq)
356.16%
Levered Free Cash Flow (ttm)
-25.56M
Research Analysis: RVLPQ
Company Insights: RVLPQ
RVLPQ does not have Company Insights